MK-6096

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for MK-6096, covering 2015-12-10 to 2016-11-07. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022) [Phase 2]

See pricing